MX2017016439A - Composicion farmaceutica oftalmologica. - Google Patents
Composicion farmaceutica oftalmologica.Info
- Publication number
- MX2017016439A MX2017016439A MX2017016439A MX2017016439A MX2017016439A MX 2017016439 A MX2017016439 A MX 2017016439A MX 2017016439 A MX2017016439 A MX 2017016439A MX 2017016439 A MX2017016439 A MX 2017016439A MX 2017016439 A MX2017016439 A MX 2017016439A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- ophthalmologic
- active agent
- therapeutically active
- solid carrier
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a composiciones farmacéuticas para el tratamiento o prevención de enfermedades o trastornos oftalmológicos, en donde la composición farmacéutica comprende un portador sólido en forma de un material no tejido o tejido hecho de fibras solubles en agua y por lo menos un agente terapéuticamente activo, en donde el portador sólido es impregnado con por lo menos el agente terapéuticamente activo, en donde el portador sólido se desintegra fácilmente tras el contacto con el ojo. También está comprendida esta composición para el uso en el tratamiento o prevención de condiciones oftalmológicas y el uso de los materiales no tejidos/tejidos descritos en este documento como portadores para por lo menos un agente terapéuticamente activo en una composición farmacéutica oftalmológica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15173997.6A EP3108874A1 (en) | 2015-06-26 | 2015-06-26 | Ophthalmologic pharmaceutical composition |
PCT/EP2016/064653 WO2016207340A1 (en) | 2015-06-26 | 2016-06-24 | Ophthalmologic pharmaceutical composition |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017016439A true MX2017016439A (es) | 2018-08-16 |
Family
ID=53510642
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017016439A MX2017016439A (es) | 2015-06-26 | 2016-06-24 | Composicion farmaceutica oftalmologica. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20180296473A1 (es) |
EP (2) | EP3108874A1 (es) |
JP (1) | JP6918711B2 (es) |
KR (1) | KR20180021065A (es) |
DK (1) | DK3313370T3 (es) |
ES (1) | ES2864638T3 (es) |
HU (1) | HUE053974T2 (es) |
MX (1) | MX2017016439A (es) |
MY (1) | MY193529A (es) |
PL (1) | PL3313370T3 (es) |
RU (1) | RU2734344C2 (es) |
WO (1) | WO2016207340A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ2016827A3 (cs) * | 2016-12-23 | 2018-02-07 | Contipro A.S. | Oftalmologický prostředek |
KR102090736B1 (ko) * | 2018-05-18 | 2020-04-23 | 서울대학교산학협력단 | 담체 복합체 및 이를 포함하는 약학 조성물 |
KR20240040272A (ko) * | 2022-09-21 | 2024-03-28 | 동국대학교 산학협력단 | 약물을 담지한 동결건조 히알루론산을 포함하는 점막 투여용 약물 전달체 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3075527A (en) * | 1960-06-02 | 1963-01-29 | Chemway Corp | Sterile medicated strips |
CA1311686C (en) * | 1986-06-25 | 1992-12-22 | John Weldon Shell | Controlled release bioerodible drug delivery system |
ATE421318T1 (de) * | 1997-02-20 | 2009-02-15 | Massachusetts Inst Technology | Darreichungsform, welche rasche dispersionseigenschaften entfaltet, anwendungsverfahren sowie verfahren zur herstellung derselben |
FR2833493B1 (fr) * | 2001-12-18 | 2005-09-23 | Ioltechnologie Production | Forme galenique solide et soluble pour l'administration occulaire de principes actifs et procede de fabrication d'un insert ophtalmique solide et soluble |
IL165910A0 (en) * | 2002-07-03 | 2006-01-15 | Pericor Science Inc | Compositions of hyaluronic acid and methods of use |
MXPA03011987A (es) * | 2003-12-19 | 2005-06-23 | Osio Sancho Alberto | Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal. |
US7323425B2 (en) * | 2004-08-27 | 2008-01-29 | Stony Brook Technology And Applied Research | Crosslinking of hyaluronan solutions and nanofiberous membranes made therefrom |
US8143391B2 (en) | 2004-09-07 | 2012-03-27 | Chugai Seiyaku Kabushiki Kaisha | Process for producing water-soluble hyaluronic acid modification |
CN1757414A (zh) * | 2005-09-09 | 2006-04-12 | 中国海洋大学 | 一种治疗眼表疾病的载药可视多糖膜片的制造方法 |
US8979931B2 (en) * | 2006-12-08 | 2015-03-17 | DePuy Synthes Products, LLC | Nucleus replacement device and method |
US20130136784A1 (en) * | 2007-10-11 | 2013-05-30 | Robert J. Staab | Methods for delivery of medication using dissolvable devices |
US20110229551A1 (en) * | 2010-03-17 | 2011-09-22 | Notus Laboratories, Inc. | Drug delivery compositions and methods using nanofiber webs |
RU2458709C1 (ru) * | 2010-12-28 | 2012-08-20 | Общество с ограниченной ответственностью "НПО ЛИОМАТРИКС" | Биопластический материал |
CZ302994B6 (cs) * | 2010-12-31 | 2012-02-08 | Cpn S.R.O. | Hyaluronová vlákna, zpusob jejich prípravy a použití |
WO2013171764A2 (en) * | 2012-04-30 | 2013-11-21 | Rubicon Research Private Limited | Ophthalmic formulations |
-
2015
- 2015-06-26 EP EP15173997.6A patent/EP3108874A1/en not_active Withdrawn
-
2016
- 2016-06-24 KR KR1020187000682A patent/KR20180021065A/ko not_active Application Discontinuation
- 2016-06-24 JP JP2017567073A patent/JP6918711B2/ja active Active
- 2016-06-24 ES ES16733411T patent/ES2864638T3/es active Active
- 2016-06-24 RU RU2018102746A patent/RU2734344C2/ru active
- 2016-06-24 MY MYPI2017704909A patent/MY193529A/en unknown
- 2016-06-24 PL PL16733411T patent/PL3313370T3/pl unknown
- 2016-06-24 HU HUE16733411A patent/HUE053974T2/hu unknown
- 2016-06-24 DK DK16733411.9T patent/DK3313370T3/da active
- 2016-06-24 MX MX2017016439A patent/MX2017016439A/es active IP Right Grant
- 2016-06-24 EP EP16733411.9A patent/EP3313370B1/en active Active
- 2016-06-24 WO PCT/EP2016/064653 patent/WO2016207340A1/en active Application Filing
- 2016-06-24 US US15/737,894 patent/US20180296473A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
RU2018102746A3 (es) | 2019-11-29 |
JP2018518514A (ja) | 2018-07-12 |
WO2016207340A1 (en) | 2016-12-29 |
RU2734344C2 (ru) | 2020-10-15 |
US20180296473A1 (en) | 2018-10-18 |
DK3313370T3 (da) | 2021-03-29 |
EP3313370B1 (en) | 2020-12-30 |
ES2864638T3 (es) | 2021-10-14 |
HUE053974T2 (hu) | 2021-07-28 |
MY193529A (en) | 2022-10-18 |
KR20180021065A (ko) | 2018-02-28 |
PL3313370T3 (pl) | 2021-10-25 |
EP3108874A1 (en) | 2016-12-28 |
JP6918711B2 (ja) | 2021-08-11 |
EP3313370A1 (en) | 2018-05-02 |
RU2018102746A (ru) | 2019-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2019008684A2 (es) | 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas para el tratamiento del cancer | |
EA201892431A1 (ru) | Олигонуклеотиды для лечения заболевания глаз | |
NZ744307A (en) | Treatment of fibrosis | |
MY171920A (en) | Prevention and treatment of ocular conditions | |
MX2017012426A (es) | Composiciones y metodos para modular la expresion de tmprss6. | |
MX2019015311A (es) | Composiciones de ésteres de ácido cannabidiólico y usos de las mismas. | |
PH12019501902A1 (en) | Ocular formulations for drug-delivery to the posterior segment of the eye | |
BR112014008759A2 (pt) | tratamento de doença ocular | |
MX2022014634A (es) | Metodos para la administracion linfatica de agentes activos. | |
CA3010568A1 (en) | Oromucosal nanofiber carriers for therapeutic treatment | |
WO2012080497A3 (en) | Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases | |
EP4324454A3 (en) | Cross-linking agents and associated methods | |
EA201991650A1 (ru) | Способы лечения неврологических расстройств | |
EA201791009A1 (ru) | Композиции, содержащие циклоспорин | |
MY193529A (en) | Ophthalmologic pharmaceutical composition | |
WO2015066302A3 (en) | Compositions, methods of use, and methods of treatment | |
MX2017004760A (es) | Formulacion esterilizada por calor que comprende quitosan y proceso para preparacion de la misma. | |
MX2021006070A (es) | Formulaciones oculares para la administracion de farmacos y proteccion del segmento anterior del ojo. | |
WO2015048188A3 (en) | Modified fibroblast growth factors for the treatment of ocular disorders | |
BR112015011693A2 (pt) | composições fibrinolíticas compreendendo bromelina e nattokinase para a prevenção e tratamento de estados flebotrombóticos | |
WO2016011297A3 (en) | Methods and related compositions for improved drug bioavailability and disease treatment | |
PH12019502145A1 (en) | Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient | |
MX2017013879A (es) | Composiciones que comprenden anakinra. | |
MX2018000379A (es) | Material no tejido tratado que tiene una afinidad por un ingrediente activo. | |
WO2016191458A3 (en) | Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |